In Vivo and Ex Vivo Evaluation of 1,3-Thiazolidine-2,4-Dione Derivatives as Euglycemic Agents

Authors:
Open Access
Publisher website
Google Scholar
Abstract
Thiazolidinediones (TZDs), used to treat type 2 diabetes mellitus, act as full agonists of the peroxisome proliferator-activated receptor gamma. Unfortunately, they produce adverse effects, including weight gain, hepatic toxicity, and heart failure. Our group previously reported the design, synthesis, in silico evaluation, and acute oral toxicity test of two TZD derivatives, compounds 40 (C40) and 81 (C81), characterized as category 5 and 4, respectively, under the Globally Harmonized System. The aim of this study was to determine whether C40, C81, and a new compound, C4, act as euglycemic and antioxidant agents in male Wistar rats with streptozotocin-induced diabetes. The animals were randomly divided into six groups ( ): the control, those with diabetes and untreated, and those with diabetes and treated with pioglitazone, C40, C81, or C4 (daily for 21 days). At the end of the experiment, tissue samples were collected to quantify the level of glucose, insulin, triglycerides, total cholesterol, and liver enzymes, as well as enzymatic and nonenzymatic antioxidant activity. C4, without a hypoglycemic effect, displayed the best antioxidant activity. Whereas C81 could only attenuate the elevated level of blood glucose, C40 generated euglycemia by the end of the treatment. All compounds produced a significant decrease in triglycerides.
Funding Information
  • EDI (SIP)/IPN (SIP20210729, SIP20210567, 226003, I010-0532-2014)
  • SIBE (SIP20210729, SIP20210567, 226003, I010-0532-2014)
  • Secretaría de Investigación y Posgrado, IPN (SIP20210729, SIP20210567, 226003, I010-0532-2014)
  • Secretaría de Ciencia, Humanidades, Tecnología e Innovación (SIP20210729, SIP20210567, 226003, I010-0532-2014)

This publication has 70 references indexed in Scilit: